LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to…
We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.
Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.
We cautiously welcome the Government's announcement on how their £50m commitment into MND research will be spent.
First major funding call announced as part of our £100m Chronic Respiratory Infection Translational Challenge
More than 300,000 people in the UK are living with bronchiectasis and more than 10,000 have been diagnosed with cystic fibrosis.
Trials will examine the impact of home monitoring and machine learning decision support algorithms for people with CF and bronchiectasis.
Seed funding will be used to scale the solution through the application of machine learning
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS